Omnio AB (private company)
See something wrong or missing? Let us know
Offices:Umeå
Industry:BiotechHealth services
Business model:B2B
Omnio AB, is a biotechnical research and development company located in Umeå, northern Sweden. The major aim for Omnio is to develop pro-inflammatory protein based drug candidates based on the plasma protein plasminogen. Plasminogen occurs naturally in sufficient levels in the circulation of healthy people, and can thus be derived through blood plasma fractionation procedures, such as the Cohn Process or ProMetic’s PPPS(TM) process.
Investors:
we tracked 1 investor
You need an account to access this feature. Log in or create one from here.
Do you have a question? Talk to us.
values in USD
Investments 35.1M
You need an account to access this feature. Log in or create one from here.
Do you have a question? Talk to us.
Companies with similar profile to Omnio AB
Name | Criteria | |
---|---|---|
![]() |
AbolerIS Pharma
47%
|
|
![]() |
Acesion Pharma
47%
|
|
![]() |
Achilles Therapeutics
47%
|
|
![]() |
Adrenomed AG
47%
|
|
![]() |
Alvotech
47%
|
|
![]() |
Antag Therapeutics
47%
|
|
![]() |
Aprea Therapeutics
47%
|
|
![]() |
Arthex Biotech S.L.
47%
|
|
![]() |
Atai Life Sciences
47%
|
|
![]() |
Biofidelity
47%
|
|